← Banking With Billy News

Biomea Fusion has opened enrollment for its COVALENT-212 study of icovamenib in type 2 diabetes, extending the candidate’s development beyond type 1 disease. El

BWB News TV • 2026-07-31 20:41 UTC • By Billy Odell Tucker-Robinson
Biomea Fusion has opened enrollment for its COVALENT-212 study of icovamenib in type 2 diabetes, extending the candidate’s development beyond type 1 disease. El
Biomea Fusion has opened enrollment for its COVALENT-212 study of icovamenib in type 2 diabetes, extending the candidate’s development beyond type 1 disease. Eligible adults are 18-75, with HbA1c of 7.0%-10.5%, and on diabetes medication.
Share this article
𝕏 X / Twitter Facebook LinkedIn WhatsApp
📚 More from Billy’s World
📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly